Skip to main content

Table 4 Progression-free survival by MIPI risk category and by analyzed cohort

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Patient cohort

Median PFS (95% CI), months

Median OS (95% CI), months

Temsirolimus 175/75 mg

Temsirolimus 175/25 mg

INV therapy

Temsirolimus 175/75 mg

Temsirolimus 175/25 mg

INV therapy

Low risk

All

n = 14

n = 15

n = 22

n = 14

n = 15

n = 22

5.3 (4.2, 10.9)

6.2 (3.5, 10.9)

2.6 (2.1, 5.4)

18.0 (11.1, 22.3)

14.5 (11.0, NA)

10.5 (6.7, 16.6)

Blastoid excluded

n = 14

n = 15

n = 22

n = 14

n = 15

n = 22

5.3 (4.2, 10.9)

6.2 (3.5, 10.9)

2.6 (2.1, 5.4)

18.0 (11.1, 22.3)

14.5 (11.0, NA)

10.5 (6.7, 16.6)

Missing values for MIPI excluded

n = 12

n = 13

n = 16

n = 12

n = 13

n = 16

10.9 (4.2, 10.9)

6.2 (1.9, 10.9)

2.9 (2.4, 9.7)

18.0* (14.1, 22.3)

14.5 (11.0, NA)

9.5 (5.3, 16.6)

Blastoid and missing values excluded

n = 12

n = 13

n = 16

n = 12

n = 13

n = 16

10.9 (4.2, 10.9)

6.2 (1.9, 10.9)

2.9 (2.4, 9.7)

18.0* (14.1, 22.3)

14.5 (11.0, NA)

9.5 (5.3, 16.6)

Intermediate risk

All

n = 24

n = 18

n = 21

n = 24

n = 18

n = 21

4.3* (2.9, 9.1)

3.4 (2.6, 3.7)

1.9 (1.6, 4.0)

12.8 (8.1, NE)

8.8 (8.1, 20.6)

12.4 (5.7, 15.1)

Blastoid excluded

n = 24

n = 16

n = 19

n = 24

n = 16

n = 19

4.3 (2.9, 9.1)

3.4 (1.8, 7.0)

1.9 (1.6, 4.0)

12.8 (8.1, NA)

8.8 (8.1, 20.6)

13.6 (5.7, NA)

Missing values for MIPI excluded

n = 22

n = 18

n = 19

n = 22

n = 18

n = 19

4.8* (3.1, 9.1)

3.4 (2.6, 3.7)

1.9 (1.3, 4.0)

14.3 (10.0, NA)

8.8 (8.1, 20.6)

12.4 (5.7, 15.1)

Blastoid and missing values excluded

n = 22

n = 16

n = 17

n = 22

n = 16

n = 17

4.8* (3.1, 9.1)

3.4 (1.8, 7.0)

1.9 (1.3, 4.6)

14.3 (10.0, NA)

8.8 (8.1, 20.6)

12.4 (5.7, NA)

High risk

All

n = 16

n = 21

n = 11

n = 16

n = 21

n = 11

4.5† (1.7, 7.4)

1.9 (1.5, 3.3)

1.6 (0.7, 1.7)

5.3 (2.0, 9.9)

4.1 (2.0, 7.2)

3.5 (2.0, 4.8)

Blastoid excluded

n = 16

n = 14

n = 9

n = 16

n = 14

n = 9

4.5‡ (1.7, 7.4)

1.9* (1.7, 5.6)

1.6 (0.9, 1.7)

5.3 (2.0, 9.9)

5.1 (3.3, 14.6)

3.7 (3.2, 20.4)

Missing values for MIPI excluded

n = 16

n = 18

n = 11

n = 16

n = 18

n = 11

4.5† (1.7, 7.4)

1.9* (1.5, 3.3)

1.6 (0.7, 1.7)

5.3 (2.0, 9.9)

4.5 (3.3, 7.2)

3.5 (2.0, 4.8)

Blastoid and missing values excluded

n = 16

n = 12

n = 9

n = 16

n = 12

n = 9

4.5‡ (1.7, 7.4)

1.9* (1.7, 5.6)

1.6 (0.9, 1.7)

5.3 (2.0, 9.9)

5.1 (3.3, 14.6)

3.7 (3.2, 20.4)

  1. * P < 0.05 versus INV.
  2. † P < 0.005 versus INV.
  3. ‡ P < 0.01 versus INV.
  4. MIPI = Mantle Cell Lymphoma International Prognostic Index; PFS = progression-free survival; CI = confidence interval; OS = overall survival; INV = Investigator’s choice of therapy.
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us